CLINICAL VARIABLES
ROOT HEALTH includes comprehensive longitudinal clinical data covering patient characteristics, diagnosis, treatment, molecular testing, follow-up, and clinical outcomes.
Clinical Variables Available in ROOT HEALTH
38 summarized variable groups across 7 clinical domains.
| Clinical Domain | Summarized Subcategory | Data Description | Data Included / Coverage | Data Value (Examples) |
|---|---|---|---|---|
| Registry / Common | Cancer registry identifiers | Registry source and identifiers used to define each cancer case in ROOT HEALTH. | Includes whether the case is linked to cancer registration data, cancer registration year/month, registration serial number, and cohort application date. Registration year refers to the year recorded through Korea's national cancer registration framework (Korea Central Cancer Registry, KCCR). | Source: registered / non-registered; Year: YYYY; Month: MM; Serial no.; Date: YYYY-MM-DD |
| Basic Information | Patient demographics | Core demographic characteristics. | Date of birth, sex, nationality status, and residential area. | Date; M/F; Korean/foreign national; province/city/district |
| Basic Information | Clinical trial participation | Participation in clinical trials. | Participation status and number of clinical trial enrollments. | Y/N; count |
| Basic Information | Cohort classification | Predefined clinical/molecular cohort flags used for research-ready patient selection. | EGFR-sensitive, ALK-positive, IO, rare-mutation, CNS metastasis and cohort-exclusion classifications. | Cohort flags / predefined categories |
| Basic Information | Visit / follow-up | Key hospital visit and follow-up dates. | Last follow-up, first oncology visit/admission, physician ID and last visit type. | YYYY-MM-DD; visit type; physician ID |
| Basic Information | Body measurements | Integrated anthropometric measurements. | Height, weight, BMI, measurement date and source. | cm; kg; BMI; YYYY-MM-DD; source |
| Follow-up & Outcomes | Vital status / death | Vital status and mortality information from integrated clinical/registry sources. | Death status/date, source of death date, cause-of-death code and cause descriptions. | Y/N; YYYY-MM-DD; ICD/code; text/source |
| Follow-up & Outcomes | Recurrence | Post-treatment recurrence information. | Recurrence status/date/source, including local and distant relapse. | Initially/Recurred; Y/N; YYYY-MM-DD; source |
| Follow-up & Outcomes | Metastasis | Date, source and site-specific metastatic disease information. | Overall metastatic date plus lung-to-lung, bone, liver, adrenal, pleural, nodal and other metastatic sites. | Y/N; YYYY-MM-DD; site; source |
| Follow-up & Outcomes | Brain metastasis | Brain metastasis characteristics and treatment information. | Brain metastasis status/date and CNS-directed treatment information. | Y/N; YYYY-MM-DD; treatment category |
| Follow-up & Outcomes | Survival outcomes | Derived survival endpoints. | Overall survival (OS), disease-free survival (DFS) and progression-free survival (PFS), including event/date/time variables. | Event Y/N; date; survival time |
| Medical History & Status | Smoking history | Smoking exposure and status. | Smoking status and quantitative smoking history. | Never/former/current; pack-year related values |
| Medical History & Status | Family history | Cancer-related family history. | Family history status and related information. | Y/N / categorical |
| Medical History & Status | Comorbidities | Pre-existing medical conditions relevant to clinical characterization. | Multiple comorbidity indicators derived from clinical information. | Y/N / condition-specific indicators |
| Medical History & Status | ECOG performance status | Functional performance status. | ECOG performance status and related timing information. | ECOG 0–4; date |
| Diagnosis | Diagnosis dates | Key dates defining cancer diagnosis. | Initial diagnosis and institution-specific diagnosis dates. | YYYY-MM-DD |
| Diagnosis | Primary diagnosis | Primary cancer diagnosis information. | Primary diagnosis name/code. | Diagnosis code / text |
| Diagnosis | Histology | Pathologic/histologic characterization of lung cancer. | Histologic diagnosis and related pathologic classification variables. | Histology category / text |
| Diagnosis | Clinical TNM stage | Clinical TNM staging. | Clinical T, N, M and overall stage across applicable AJCC editions. | cT / cN / cM / Stage |
| Diagnosis | Pathologic TNM stage | Pathologic TNM staging. | Pathologic T, N, M and overall stage across applicable AJCC editions. | pT / pN / pM / Stage |
| Diagnosis | Multiple primary cancer | Information on synchronous/metachronous additional primary cancers. | Presence and characteristics of additional primary malignancies. | Y/N; site/diagnosis/date |
| Examination | EGFR | EGFR molecular testing summarized at the gene level rather than by repeated result fields. | Initial and repeat EGFR mutation results, detailed mutation information, EMR-derived results and cell-free testing. Initial/repeat; tissue and cell-free molecular results. | Positive/negative/no mutation; mutation notation; date |
| Examination | ALK | ALK testing summarized across available modalities. | ALK IHC, FISH and EMR-derived ALK results. IHC; FISH; EMR-derived result. | Positive/negative; score/result; date |
| Examination | PD-L1 | PD-L1 expression testing summarized across assay types. | PD-L1 results from major IHC assays. 22C3; SP263; SP142; other assay. | TPS/percentage or categorical result; date |
| Examination | NGS | Next-generation sequencing information. | NGS test availability and related test/result information. NGS. | Panel/test information; date/result |
| Examination | ROS1 | ROS1 testing summarized across available modalities. | ROS1 PCR and IHC results. PCR; IHC. | Detected/not detected or positive/negative; date |
| Examination | BRAF | BRAF molecular testing. | BRAF mutation test result and related mutation information. Molecular mutation testing. | Positive/negative; mutation notation; date |
| Examination | Bronchoscopy | Bronchoscopic examination information. | Bronchoscopy procedure, timing and related examination information. Bronchoscopy. | Procedure/result/date |
| Treatment | Overall treatment sequence | Longitudinal treatment history summarized as sequential treatment episodes. | Treatment type, intent, timing and related treatment information across sequential treatment records. Up to 7 sequential treatment records plus last-treatment summary. | Treatment type; date; intent; sequence |
| Treatment | Surgery | Lung cancer surgical treatment history. | Surgical information including procedure-related variables and repeated operations. Up to 3 surgery episodes. | Procedure; date; surgical details |
| Treatment | Salvage treatment | Salvage/local treatment after prior therapy. | Salvage treatment type and related information. Salvage treatment. | Treatment type / date |
| Treatment | Neoadjuvant systemic therapy | Preoperative systemic treatment. | Regimen and treatment-course information for neoadjuvant therapy. Up to 2 neoadjuvant treatment lines/courses. | Regimen; start/end date; cycle/response-related fields |
| Treatment | Adjuvant systemic therapy | Postoperative systemic treatment. | Regimen and treatment-course information for adjuvant therapy. Up to 3 adjuvant treatment lines/courses. | Regimen; start/end date; cycle/response-related fields |
| Treatment | Definitive therapy | Definitive non-surgical treatment including systemic/chemoradiation-related treatment records. | Regimen and treatment-course information for definitive therapy. Up to 3 definitive treatment lines/courses. | Regimen; start/end date; treatment-related fields |
| Treatment | Durvalumab | Consolidation durvalumab treatment information. | Durvalumab treatment timing and related variables. Durvalumab. | Treatment dates / treatment status |
| Treatment | Palliative systemic therapy | Systemic therapy for recurrent/metastatic disease, consolidated rather than displayed line-by-line. | Regimen, dates and treatment-course information for each palliative line. Up to 11 palliative lines (1L–11L). | Line; regimen; start/end date; cycle/response-related fields |
| Treatment | Targeted / immunotherapy exposure | Therapy-specific summary variables across treatment history. | EGFR TKI, ALK TKI, PD-(L)1 inhibitor and other TKI exposure. EGFR TKI; ALK TKI; PD-(L)1 inhibitor; other TKI. | Y/N; line(s); treatment information |
| Treatment | Sequential chemoradiotherapy | Sequential chemotherapy/radiotherapy treatment information. | Treatment sequence and related chemoradiotherapy variables. Sequential CRT. | Treatment type; date; sequence |
Registry note.
Korea's national cancer registration program is coordinated through the Korea Central Cancer Registry (KCCR),
a nationwide cancer registration program operated under the National Cancer Center.
In this summary, “cancer registration year” refers to the year recorded for the cancer case in that registration framework.
Back to Data